| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1586/14787210.5.2.177 |
| P698 | PubMed publication ID | 17402833 |
| P50 | author | G Ralph Corey | Q115862748 |
| P2093 | author name string | Zeina A Kanafani | |
| P2860 | cites work | Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers | Q24679375 |
| Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia | Q46716065 | ||
| Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves | Q46908684 | ||
| Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. | Q50895662 | ||
| Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. | Q51195354 | ||
| Daptomycin: a novel agent for Gram-positive infections. | Q53852746 | ||
| Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. | Q54034073 | ||
| Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin | Q28268465 | ||
| Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin | Q33233009 | ||
| Development of daptomycin for gram-positive infections | Q33920377 | ||
| Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi | Q33981366 | ||
| Resistance studies with daptomycin | Q33982318 | ||
| Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus | Q34073487 | ||
| Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations | Q34230034 | ||
| Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center | Q34270638 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry | Q34415953 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects | Q34882125 | ||
| Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms | Q34936759 | ||
| In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains | Q35023234 | ||
| Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus | Q35166213 | ||
| Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy | Q36257693 | ||
| In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin | Q36625774 | ||
| Population pharmacokinetics of daptomycin | Q36670451 | ||
| Once-daily dosing in dogs optimizes daptomycin safety | Q39537062 | ||
| Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers | Q39650862 | ||
| Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032 | Q39828406 | ||
| Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis | Q40166184 | ||
| Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. | Q40602489 | ||
| Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates | Q40902642 | ||
| Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus | Q41269406 | ||
| Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin | Q42042890 | ||
| Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin | Q42150957 | ||
| Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy | Q42708842 | ||
| Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates | Q42925097 | ||
| Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections | Q43532746 | ||
| In vitro bactericidal activity of daptomycin against staphylococci | Q43895572 | ||
| Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis | Q43931567 | ||
| Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus | Q44459200 | ||
| Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model | Q44548730 | ||
| Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms | Q44777352 | ||
| Moderate liver impairment has no influence on daptomycin pharmacokinetics | Q44938154 | ||
| Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections | Q45230598 | ||
| Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. | Q46433642 | ||
| In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections | Q46471549 | ||
| Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact | Q46494181 | ||
| Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection | Q46607570 | ||
| P433 | issue | 2 | |
| P921 | main subject | gram-positive bacteria | Q857288 |
| (2S)-daptomycin | Q63413234 | ||
| P304 | page(s) | 177-184 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections | |
| P478 | volume | 5 |
| Q46768796 | A successful protocol for daptomycin desensitization |
| Q38176042 | Antibiotic resistance in Enterococcus faecium clinical isolates |
| Q37333194 | Are glycopeptides still appropriate and convenient for empiric use? |
| Q39447286 | Cyclic Peptides as Novel Therapeutic Microbicides: Engineering of Human Defensin Mimetics. |
| Q47116570 | Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost |
| Q37150644 | Daptomycin for the treatment of major gram-positive infections after cardiac surgery. |
| Q35026595 | Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens |
| Q90054184 | Depiction of secondary metabolites and antifungal activity of Bacillus velezensis DTU001 |
| Q37213029 | Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine |
| Q33798246 | Penetration of daptomycin into bone and synovial fluid in joint replacement |
| Q60930910 | Polymicrobial anaerobic infection with a deep abscess in the supraspinous fossa following a subacromial corticosteroid injection |
| Q38515064 | Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles |
| Q48756705 | Treatment of cardiovascular implantable electronic device infection with daptomycin |
| Q84028196 | [Daptomycin in the context of antimicrobial resistance in Gram-positive bacteria] |
Search more.